Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment...
June 22, 2021 19:22 ET | Source: Telix Pharmaceuticals Limited

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

MELBOURNE, Australia, June 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed in a Phase I study of...
April 10, 2020 18:00 ET | Source: BeiGene, LTD.

China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

BEIJING, China and CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
March 24, 2020 08:00 ET | Source: Aravive, Inc.

Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)

HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored...
December 01, 2016 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

LA JOLLA, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today presented preclinical data highlighting the identification...
May 11, 2016 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports First Quarter 2016 Financial Results

LA JOLLA, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company, today reported financial results for the first quarter ended March...
December 03, 2015 07:00 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Data Presentation on Lead Product Candidate Tipifarnib at the Upcoming ASH Meeting

LA JOLLA, Calif., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that new data from a Phase 3 trial of tipifarnib, the...
December 01, 2015 07:00 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at the Oppenheimer 2015 Healthcare Conference

LA JOLLA, Calif., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief...
November 30, 2015 18:40 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at Upcoming Investor Conference

LA JOLLA, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief...